FDA's Dickinson Named Acting Chief Counsel Following Tyler’s Departure
This article was originally published in The Rose Sheet
Executive Summary
FDA has tapped Elizabeth Dickinson for acting chief counsel, effective Aug. 7. Dickinson is taking the post on an interim basis while the agency seeks a permanent successor to Ralph Tyler.
You may also be interested in...
In Brief
Democratic Senators ask FDA to set maximum lead limits for lipstick. More news in brief.
FDA News In Brief
Dickinson installed as permanent chief counsel; Schwabe’s Umcka homeopathics deemed new drugs for cold/flu claims; inadequate GMPs weigh on Vitagenic; more FDA In Brief.
FDA News In Brief
Dickinson installed as permanent chief counsel; Schwabe’s Umcka homeopathics deemed new drugs for cold/flu claims; inadequate GMPs weigh on Vitagenic; more FDA In Brief.